Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Millennium Pharmaceuticals, Inc.
With
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients 18 years or older.
Newly Diagnosed non-GCB subtype of DLBCL (Stage II, III or IV).
At least 1 measurable site of disease.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Female subjects must be postmenopausal (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control before entry and throughout the study; and have a negative pregnancy test at screening.
Male subjects must agree to use a double barrier method of birth control
You may not be if
Prior treatment with VELCADE.
Prior extended radiotherapy or chemotherapy for lymphoma
More than 150 mg/m2 of prior doxorubicin
Major surgery within 3 weeks of study.
Peripheral neuropathy or neuralgia of Grade 2 or worse.
Active CNS lymphoma
Diagnosed or treated for a malignancy other than NHL, with some exceptions
Pregnant or breast feeding
Active systemic infection
Documented of suspected human immunodeficiency virus (HIV)/AIDS
Uncontrolled or severe cardiovascular disease
Known allergies, hypersensitivity or intolerance to study drugs
Serious medical condition that could interfere with study
Concurrent treatment with another investigational agent
Clareo Health | Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
